Patents Examined by Anish Gupta
  • Patent number: 8765687
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: July 1, 2014
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
  • Patent number: 8530432
    Abstract: The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: September 10, 2013
    Assignee: NeoPro Labs, LLC
    Inventor: Hanna Skubatch
  • Patent number: 8507426
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ?ID?NO:?100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ?ID?NO:?104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ?ID?NO:?105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ?ID?NO:?106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ?ID?NO:?107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ?ID?NO:?109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: August 13, 2013
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Patent number: 8492159
    Abstract: The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 23, 2013
    Assignee: NeoPro Pain, Inc.
    Inventor: Hanna Skubatch
  • Patent number: 8486886
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: July 16, 2013
    Assignee: Allergan, Inc.
    Inventors: K. Roger Aoki, Michael W. Grayston, Stephen R. Carlson, Judith M. Leon
  • Patent number: 8476224
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: July 2, 2013
    Assignee: Novartis AG
    Inventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. Lamarche
  • Patent number: 8455620
    Abstract: The present invention relates to a novel phytase enzyme, a novel isolated nucleic acid molecule coding the enzyme, and a novel Yersinia intermedia having phytase activity. Particularly, the present invention relates to the phytase having (a) Theoretical molecular weight 45.5 kDa, (b) high specific activity 3960±248 U/mg, (c) high stability at high temperature and wide pH, (d) optimal pH of 4.0-5.0, (e) optimal temperature of 50-60° C., (f) high resistance to pepsin and trypsin. The phytase is very suitable to be used in feed of monogastrics as feed additive. The present invention also relates to a recombinant vector comprising said nucleic acid molecule, a recombinant host cell (e.g., Pichia pastoris) harboring said recombinant vector, and a method for producing phytase using the recombinant host cell. The present invention further provides a feed additive comprising said phytase and/or host cells expressing a phytase as effective ingredient.
    Type: Grant
    Filed: April 30, 2006
    Date of Patent: June 4, 2013
    Assignee: Feed Research Institute Chinese Academy of Agricultural Sciences
    Inventors: Bin Yao, Huiying Luo, Huoqing Huang, Yaru Wang, Tiezheng Yuan, Xiuyun Shi, Yingguo Bai, Kun Meng, Peilong Yang
  • Patent number: 8415454
    Abstract: A process for manufacturing a cyclic peptide which comprises providing a cyclic peptide bonded to a Merrifield-type resin and cleaving the cyclic peptide from the Merrifield type resin by transesterification.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: April 9, 2013
    Assignee: Solvay (Société Anonyme)
    Inventors: Satish Joshi, Shima Joshi, Bernhard Freimann, Manuel Ramos, Roland Callens
  • Patent number: 8415307
    Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 9, 2013
    Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
    Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
  • Patent number: 8410044
    Abstract: The invention concerns new Bacitracin compounds containing methylene-isoleucine.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 2, 2013
    Assignee: Xellia Pharmaceuticals Aps
    Inventors: Martin Mansson, Christine Senstad
  • Patent number: 8404692
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR11, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH?CH; X is a hydrocarbyl group optionally substituted by one or more R12 groups; R10 and R11 are each independently II or alkyl; R1-R4 are each independently II or (CII2)mR12, where m is O, 1, 2, or 3; each R12 is independently (CH2)aR16, where each R16 is independently selected from O(CH2)bR13, R13, COR13, COOR13, CN, CONR13R14, NR13R14, NR13COR14, SR13, SOR13, SO2R13, NR13SO2R14, SO2OR13, SO2NR13R14, halogen, CF3, and NO2, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; R13 and R14 are each independently H or (CH2)aR15, where n is 0, 1, 2, or 3; and each R15 is independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: March 26, 2013
    Assignee: Cyclacel Limited
    Inventors: Stuart Jones, Robert Westwood, Mark Thomas, Janice McLachlan, Kenneth Duncan, Fred Scaerou, Daniella I. Zheleva
  • Patent number: 8404802
    Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: March 26, 2013
    Assignee: GE Healthcare AS
    Inventors: Alan Cuthbertson, Bard Indrevoll
  • Patent number: 8404646
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: March 26, 2013
    Assignees: Cornell Research Foundation, Inc., Institut de Recherches Cliniques de Montreal
    Inventors: Peter W. Schiller, Hazel H. Szeto, Kesheng Zhao
  • Patent number: 8399403
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: March 19, 2013
    Assignee: Medarex, Inc.
    Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Zhi-Hong Li, Bilal Sufi
  • Patent number: 8383595
    Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): and a contact lens which retains and/or contains the composition are provided.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: February 26, 2013
    Assignees: Kinki University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Atsufumi Kawabata, Hiroyuki Nishikawa, Yoshiko Kawai
  • Patent number: 8372798
    Abstract: Provided is a pharmaceutical composition involving a concentrated mixture of a precipitated protein and a liquid medium and a method for manufacturing the concentrated mixture. The concentrated mixture is manufacturable by precipitation of a protein with a biocompatible polymer precipitating agent, followed by removal of sufficient liquid to concentrate the resulting mixture to the desired degree. The precipitated protein can be stored for a significant time in the concentrated mixture, such as intermediate between processing stages during manufacture operations.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 12, 2013
    Assignee: Endo Pharmaceuticals Colorado, Inc.
    Inventors: John F. Carpenter, Jeffrey B. Etter, Adrian C. Samaniego
  • Patent number: 8372870
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: February 12, 2013
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Patent number: 8372888
    Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: February 12, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
  • Patent number: 8367620
    Abstract: Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: February 5, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Rolando Eduardo Rodriguez Fernandez, Ania De La Nuez Veulens, Mario Pablo Estrada Garcia, Rebeca Martinez Rodriguez, Glay Chinea Santiago, Osvaldo Reyes Acosta, Julio Raul Fernandez Masso, Diana Garcia del Barco Herrera, Jorge Amador Berlanga Acosta, Alexis Musacchio Lasa
  • Patent number: 8367621
    Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: February 5, 2013
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara